Data for Second-Line or Later Ramucirumab Show Consistent Be

Treatment with ramucirumab in the second line after first-line lenvatinib monotherapy or the combination of atezolizumab and bevacizumab, or as third-line treatment following both regimens, elicited efficacy comparable with second-line ramucirumab following treatment with sorafenib in patients with advanced hepatocellular carcinoma.

Related Keywords

Barcelona , Comunidad Autonoma De Cataluna , Spain , Japan , Japanese , Kazufumi Kobayashi , Department Of Gastroenterology , International Liver Cancer Association Conference , School Of Medicine Chiba University , Liver Cancer Association , Regarding Child Pugh , Graduate School , Chiba University , Liver Cancer , Hcc , Hepatocellular Carcinoma , Treatment Delays , Hcc Treatment Delays , 2022 International Liver Cancer Association Conference , Bilca , 2022 Ilca , Ramucirumab ,